Former Chief Executive Officer and Board Member, Axonics

Former Chief Executive Officer and Board Member at Axonics (2013–2024), a neuromodulation company acquired by Boston Scientific, with over 40 years of experience in medtech across cardiology, urology, and implantable devices. Has completed nearly $5 billion in transactions with Boston Scientific over the past 18 months, including multiple acquisitions in neurostimulation, peripheral nerve stimulation, and renal denervation, and serves on multiple public and private company boards. Brings deep expertise in venture-to-acquisition pathways, strategic M&A diligence, post-merger integration, and Boston Scientific's acquisition strategy and leadership.